August 09, 2021
The targeted radioligand therapy achieved several other key end points beyond overall survival and radiographic progression-free survival.
August 06, 2021
Ribociclib was explored in combination with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer.
Pieczonka also discusses toxicity differences between VERU-111 and docetaxel.
“I think as these [advanced imaging] agents come out, we're going to see more and more data on this topic,” says Ketan K. Badani, MD.
August 05, 2021
The PSMA-PET imaging agents Piflufolastat F 18 and Gallium 68 PSMA-11 are approved by the FDA for managing patients with prostate cancer.
Christopher Pieczonka, MD, discusses where the novel agent sabizabulin (VERU-111) would fit in the metastatic castration-resistant prostate cancer paradigm if it succeeds in an ongoing phase 3 trial.
August 04, 2021
The benefit was more pronounced in patients who received only 1 treatment—enzalutamide or abiraterone—and no docetaxel.
August 03, 2021
Michael J. Morris, MD, discusses the rise of radiopharmaceuticals in prostate cancer and, in particular, the success of 177Lu-PSMA-617.
July 09, 2021
"The use of 177Lu-PSMA-617 significantly extended both the imaging-based survival and overall survival," writes Badar M. Mian, MD.
July 06, 2021
Dr. Neal D. Shore discusses multidisciplinary care in prostate cancer against the backdrop of the ODENZA trial, which assessed patient preference between darolutamide and enzalutamide.
